Drug Trial Radar · NCT05136664
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
262
Actual
Start
Feb 10, 2022
Primary completion
Nov 18, 2025
Study completion Nov 18, 2025
Sponsor
- Lead sponsor
- Vifor Fresenius Medical Care Renal PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Nov 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B) and a 2-week follow-up period.
Conditions
- Hyperkalemia
- Renal Insufficiency, Chronic
Interventions
Patiromer Powder for Oral Suspension (Part A)Drug
Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels. The content of each packet should be mixed with water, apple or cranberry juice before administration.
Placebo (Part B)Drug
Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
Patiromer Powder for Orals Suspension (Part B)Drug
Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels. The content of each packet should be mixed with water, apple or cranberry juice before administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change from baseline in the serum potassium (sK+)Time frame: Week 4
- Part B: Change from Week 4 in sK+Time frame: The earlier of: Week 8 or the date when RAASi therapy is first decreased or discontinued
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site 009
Hefei, Anhui, China
Investigator Site 008
Hefei, Anhui, China
Investigator Site 016
Beijing, Beijing Municipality, China
Investigator Site 012
Lanzhou, Gansu, China
Investigator Site 003
Lanzhou, Gansu, China
Investigator Site 030
Nanning, Guangxi, China
Investigator Site 024
Nanyang, Henan, China
Investigator Site 010
Wuhan, Hubei, China
Investigator Site 006
Changsha, Hunan, China
Investigator Site 002
Changzhou, Jiangsu, China
Investigator Site 019
Nanjing, Jiangsu, China
Investigator Site 021
Wuxi, Jiangsu, China
Investigator Site 005
Xuzhou, Jiangsu, China
Investigator Site 013
Zhenjiang, Jiangsu, China
Investigator Site 007
Changchun, Jilin, China
Investigator Site 018
Yinchuan, Ningxia, China
Investigator Site 028
Shanghai, Pudong New Area, China
Investigator Site 015
Shanghai, Shanghai Municipality, China
Investigator Site 022
Taiyuan, Shanxi, China
Investigator Site 011
Yuncheng, Shanxi, China
Investigator Site 004
Chengdu, Sichuan, China
Investigator Site 014
Tianjin, Tianjin Municipality, China
Investigator Site 027
Zhuzhou, Tianyuan District, China
Investigator Site 023
Ürümqi, Xinjiang, China
Investigator Site 001
Hangzhou, Zhejiang, China
Investigator Site 020
Hanzhou, Zhejiang, China
Investigator Site 026
Jiaxing, Zhejiang, China
Investigator Site 025
Jinhua, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.